E-LIB Suche - Ergebnisse für: Lavie, D.

1

An open‐label phase 1/2 study of favezelimab plus pembroliz..:

Lavie, D. ; Johnson, N. ; Borchmann, P....
Hematological Oncology. 41 (2023) S2 - p. 364-366 , 2023

Link: https://doi.org/10.1002/..

2

WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VED..:

Fosså, A. ; Ozcan, M. ; Song, Y....
Hematological Oncology. 41 (2023) S2 - p. 208-209 , 2023

Link: https://doi.org/10.1002/..

3

FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLAS..:

Armand, P. ; Zinzani, P. L. ; Timmerman, J....
Hematological Oncology. 41 (2023) S2 - p. 163-165 , 2023

Link: https://doi.org/10.1002/..

4

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOU..:

Vannucchi, A. ; Mesa, R. ; Gerds, A....
HemaSphere. 6 (2022) - p. 940-941 , 2022

Link: https://doi.org/10.1097/..

5

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKA..:

Gregory, G. ; Timmerman, J. ; Lavie, D....
HemaSphere. 6 (2022) - p. 976-977 , 2022

Link: https://doi.org/10.1097/..

6

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MM..:

Verstovsek, S. ; Vannucchi, A. ; Gerds, A....
HemaSphere. 6 (2022) - p. 96-97 , 2022

Link: https://doi.org/10.1097/..

7

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKA..:

Herrera, A. F. ; Lavie, D. ; Johnson, N. A....
HemaSphere. 6 (2022) - p. 977-978 , 2022

Link: https://doi.org/10.1097/..

8

Interim PET-CT–guided therapy in elderly patients with Hodg..:

Bentur, O. S. ; Dann, E. J. ; Paran, E....
Annals of Hematology. 98 (2019) 7 - p. 1665-1674 , 2019

Link: https://doi.org/10.1007/..

9

Machine learning predictive modeling for mechanical thrombe..:

Arndt, S ; Bennett, G ; Lavie, J...
Journal of Vascular and Interventional Radiology. 28 (2017) 2 - p. S109-S110 , 2017

Link: https://doi.org/10.1016/..

10

Cardiac hemodynamics before, during and after elective cesa..:

Ram, M ; Lavie, A ; Lev, S...
Journal of Perinatology. 37 (2017) 7 - p. 793-799 , 2017

Link: https://doi.org/10.1038/..

11

Outcome predictors in elderly Hodgkin's lymphoma patients p..:

Avivi, I. ; Paran, E. ; Bentur, O....
Hematological Oncology. 35 (2017) S2 - p. 309-310 , 2017

Link: https://doi.org/10.1002/..

12

Factors related to the development of acquired von Willebra..:

Rottenstreich, A. ; Kleinstern, G. ; Krichevsky, S....
European Journal of Internal Medicine. 41 (2017) - p. 49-54 , 2017

Link: https://doi.org/10.1016/..

13

Trends and distribution of oral and pharyngeal lymphoma in ..:

Zini, A ; Atia‐Joachim, D ; Sgan–Cohen, HD..
Oral Diseases. 18 (2012) 7 - p. 700-706 , 2012

Link: https://doi.org/10.1111/..

14

Mitophagy mediated by Rheb and the maintenance of mitochond..:

Melser, S. ; Chatelain, E. Hebert ; Lavie, J....
Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1817 (2012) - p. S73 , 2012

Link: https://doi.org/10.1016/..

15

The Functional Groupings of α-Elaterin (Cucurbitacin E):

Lavie, D
Journal of Pharmacy and Pharmacology. 10 (2011) 1 - p. 782-782 , 2011

Link: https://doi.org/10.1111/..